Drug
Ro4917838
Ro4917838: highest development phase Phase 3, developed by Roche. 1 trial record tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Roche
Trials
| Drug | Phase | Indication |
|---|---|---|
| RO4917838 NCT01235520 | Phase 3 | Schizophrenia |
Latest
No recent events.
Follow Ro4917838 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.